Feeding 9 Billion: Innovations in Agricultural Modeling
The results apply to celecoxib, an analgesic, anti-inflammatory substance that works by inhibiting the effect of the inflammatory enzyme, Cox-2. In a study presented in Clinical Cancer Research, the research group has shown that celecoxib is also active against neuroblastoma, a type of tumour that depends on Cox-2 for its growth and proliferation.
The scientists have shown that celecoxib has an inhibitory and preventative effect on tumour development in rats. The substance also proved able to reinforce the effect of different cytostatics currently in use in the treatment of neuroblastoma.
“The painkiller can check the rapid division and growth of the cancer cells and block the blood vessels that supply the tumour with oxygen and nutrients,” says John Inge Johnsen, researcher in child cancer at Karolinska Institutet.
The researchers conclude that celecoxib is a potential anti-neuroblastoma drug, possibly in combination with other drugs.
”But it’s a matter of finding the right combination, as celecoxib can also counteract the tumouricidal effects of certain cytostatics,” says Per Kogner, Professor at Karolinska Institutet and paediatrician at the Astrid Lindgren Children’s Hospital in Stockholm.
The results from cell cultures and animals were obtained at concentrations that the scientists had previously measured in children receiving the medicine. They now plan to proceed to clinical trials, which will determine the way in which celecoxib can be used to treat neuroblastoma in children.
The research was conducted with the support of the Children’s Cancer Foundation and the Swedish Cancer Society.
Publication:
“Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo”
Clinical Cancer Research, 1 February 2007
For further information, please contact:
Dr John Inge Johnsen
Phone: +46 (0)8-517 775 15
Mobile: +46 (0)70-664 06 43
Email: John.Inge.Johnsen@ki.se
Professor Per Kogner
Phone: +46 (0)8-517 735 34
Mobil: +46 (0)70-571 39 07
Email: Per.Kogner@ki.se
Press Officer Katarina Sternudd
Phone: +46-8-524 838 95
Email: katarina.sternudd@ki.se
Most Read Articles
